Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females Group B Streptococcus (GBS) is the leading cause of ...

SUNNYVALE, Calif., May 2, 2018 /PRNewswire/ -- Cepheid announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and waiver under the Clinical Laboratory ...

Cepheid’s CPHD rapid influenza and RSV assay – the Xpert Flu+RSV Xpress test – recently won the U.S. FDA 510(k) marketing approval and the Clinical Laboratory Improvement Achievements (CLIA) waiver.

New "plus" version of test adds a 3rd gene target to enhance detection of future SARS-CoV-2 variants SUNNYVALE, Calif., Oct. 14, 2021 /PRNewswire/ -- Cepheid today announced it has received the CE ...

Multiplex Vaginal Panel (MVP) delivers faster identification of three distinct conditions within an hour SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received ...

Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females With the capability of returning positive results as ...

New "plus" version of test adds a 3rd gene target to enhance detection of future SARS-CoV-2 variants SUNNYVALE, Calif., May 19, 2022 /PRNewswire/ -- Cepheid today announced it has received the CE mark ...

SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP. This ...